Andere Sprachen Annexin Pharmaceuticals AB

Aktien

A2DX74

SE0009664154

ANNX

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 14:16:59 19.04.2024			% 5 Tage	% 1. Jan.
0.27 ^SEK	-1.10%		-6.57%	+3.85%

12.04.	Annexin Pharmaceuticals AB (publ) meldet Ergebniszahlen für das erste Quartal zum 31. März 2024	CI
09.02.	Annexin Pharmaceuticals AB (publ) meldet Ergebniszahlen für das vierte Quartal und das Gesamtjahr bis zum 31. Dezember 2023	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

BioStock: Annexin towards completion of phase II study and share issue	18.04.
Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2024	12.04.
Annexin resolves on a rights issue of SEK 45.1 million guaranteed to 90 percent, subject to approval by the 2024 Annual General Meeting, which has been decided to be brought forward	28.03.
BioStock: Strong start for Annexin in 2024	14.02.
Annexin Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	09.02.
Update on Annexin´s RVO study confirms promising signals of effect	08.02.
Annexin Pharmaceuticals AB Provides Update on RVO Study Confirms Promising Signals of Effect	08.02.
Annexin presents at Redeye’s Fight Cancer event on January 24	18.01.
Annexin announces outcome of the rights issue and resolves on directed issues to guarantors and lenders	18.12.
The subscription period in Annexin Pharmaceuticals’ rights issue begins today	30.11.
Annexin Pharmaceuticals publishes prospectus in connection with forthcoming rights issue	28.11.
First patients treated with higher dose without adverse events in Annexin's RVO study	23.11.
Annexin granted additional patent protection in the US	14.11.
Annexin Pharmaceuticals AB Announces Additional Patent Protection in the US	14.11.
First patient treated in the second dose group in Annexin's RVO study	25.10.23
First patient treated in the second dose group in Annexin's RVO study	25.10.23
Annexin Pharmaceuticals AB Announces First Patient Treated in the Second Dose Group in RVO Study	25.10.23
Annexin resolves a SEK 35.6 million fully guaranteed rights issue, subject to approval of an Extraordinary General Meeting	24.10.23
BioStock: Annexin's CSO on progress in cancer initiative	18.10.23
Annexin Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	18.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Annexin Pharmaceuticals AB

Aktien

A2DX74

SE0009664154

ANNX

Andere Sprachen

Filter